AngA-modified bone marrow mesenchymal stem cell-derived small extracellular vesicles-liposome hybrid nanoparticles loaded with Glabridin protect against doxorubicin-induced cardiotoxicity by enhancing autophagic flux via the ATG5–ATG12–ATG16L1 comple
Doxorubicin-induced cardiotoxicity (DIC) limits its clinical application and poses a significant risk to cancer patients, with impaired autophagic flux considered a core mechanism underlying DIC. Although glabridin (Gla) exhibits prominent cardioprotective effects, its poor water solubility and limited myocardial-targeting capability hinder its clinical translation. Therefore, improving the myocardial-targeting properties of Gla and restoring autophagy are critical for the treatment of DIC. In this study, we prepared angiotensin A (AngA)‑modified bone marrow mesenchymal stem cell (BMSC)-derived small extracellular vesicle (sEV)‑liposome hybrid nanoparticles and loaded them with Gla (AngA-sEV-Lip@Gla). We evaluated their myocardial-targeting capability, therapeutic efficacy against DIC, and ability to restore autophagic flux. Click chemistry-activity-based protein profiling (CC-ABPP) and site-directed mutagenesis were employed to identify the molecular target and signaling pathway of Gla. Our results demonstrated the successful establishment of AngA-sEV-Lip@Gla. In vitro and in vivo experiments showed that AngA-sEV-Lip@Gla efficiently targeted myocardial tissue and achieved favorable lysosomal escape. AngA-sEV-Lip@Gla also markedly alleviated DOX-induced cardiomyocyte injury, oxidative stress, and mitochondrial dysfunction, while ameliorating cardiac dysfunction, myocardial pathological damage, and fibrosis in DIC model mice. Mechanistic studies indicated that Gla might act at the MET173 site of ATG5 to upregulate the expression of the ATG5–ATG12–ATG16L1 complex, thereby restoring blocked autophagic flux in cardiomyocytes and exerting cardioprotective effects. In summary, AngA-sEV-Lip@Gla targets the MET173 site of ATG5 to modulate the ATG5–ATG12–ATG16L1 complex and restore autophagic flux, thereby effectively protecting against DIC. Our study provides novel mechanistic insights and experimental support for the clinical prophylaxis and treatment of DIC.
Authors
- Liang Kong (ORCID: https://orcid.org/0000-0002-0495-9193)
- Ruibo Guo
- Xuetao Li (ORCID: https://orcid.org/0000-0002-0608-4669)
- Liyan Wang (ORCID: https://orcid.org/0000-0002-2713-7416)
- Yani Zhang (ORCID: https://orcid.org/0000-0002-4028-5448)
- Yi-fei Gao
- Zheng Li
- Ying Zheng
- Jia-hua Wang
Institutions
- Liaoning University of Traditional Chinese Medicine (CN)
- Affiliated Hospital of Liaoning University of Traditional Chinese Medicine (CN)
- China Academy of Chinese Medical Sciences (CN)
Publication Details
- Journal
- Journal of Nanobiotechnology
- Published
- 2026-11-18
- DOI
- https://doi.org/10.1186/s12951-026-05275-4
- Primary Topic
- Nanoparticle-Based Drug Delivery
- Type
- article
- Field-Weighted Citation Impact
- 0.00